Abstract: The aim of study was to evaluate the expression pattern of Alpha-methylacyl-CoA Racemase (AMACR) in prostate tumors. In order to examine the relationship between AMCAR expression and tumor, we analyzed a total of 10 cases of benign prostatic hyperplasia and 20 cases of prostate adenocarcinoma . Expressions pattern of AMCAR were analysed and found that only one case (10%) of benign prostatic hyperplasia showed expression whereas 19 cases (95%) of prostate adenocarcinoma showed expression at different levels of intensity. The difference in expression pattern among benign prostatic hyperplasia and prostate adenocarcinoma was statically significant (p>0.05). Expression profile were further categorised according to grade of the tumor and found that AMCAR was expressed in 4 (100%), 6 (100%) and 9 (90%) in well, moderate and poor differentiated prostate adenocarcinoma respectively. This difference of expression among the different types of grade was statistically insignificant (p>0.05). Our results concluded that AMCAR is a valuable diagnostic and prognostic marker of prostate cancer and one of the vital factors in pathogenesis of prostrate adenocarcinoma.